News & Literature

PRESS RELEASES

Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer

Basking Ridge, N.J. – January 15, 2009 – Regado Biosciences, Inc., announced today the appointment of Steven L. Zelenkofske, D.O., F.A.C.C. to the position of Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer, effective immediately.  He will report to David J. Mazzo, Ph.D., the Company’s President and Chief Executive Officer.

Dr. Mazzo stated, “Steven has led clinical programs for more than 15 development-stage and commercialized cardiovascular products during his pharmaceutical career and has extensive experience as a principal investigator on a number of important trials in cardiovascular medicine.  His track record will be critical as Regado advances its lead therapeutic candidate, the REG1 Anticoagulation System, through late-stage clinical development.”  Regado recently completed enrollment in a Phase IIa clinical study (REVERSAL-PCI) of REG1 in patients undergoing elective percutaneous coronary intervention.

Dr. Zelenkofske’s addition completes the new executive team at Regado.  He joins recently appointed Senior Vice President of Regulatory Affairs and Quality Assurance, Dr. Alex Giaquinto and Ellen McDonald, the recently announced Senior Vice President of Business Operations and Chief Business Officer.

Most recently, Dr. Zelenkofske served as Vice President, Cardiovascular/Thrombosis Medical Unit – US at Sanofi-Aventis Pharmaceuticals and, prior to this, as Vice President of Clinical Sciences and Chief Patient Safety Officer for Boston Scientific Corporation’s Cardiac Rhythm Management (CRM) Group.  At both companies, Dr. Zelenkofske led the development and implementation of cardiovascular pre- and post-market clinical strategy.  Prior to this, he was a senior director with Novartis Pharmaceuticals, where he held positions of increasing responsibility within its cardiovascular division, attaining the position of Senior Medical Director, US Clinical Development, Hypertension and CV Section Head.  Dr. Zelenkofske also served as Director of CV Research and Clinical Director of Electrophysiology Laboratory at the Heart Care Group, where he was a physician investigator for a number of pivotal cardiovascular clinical trials, including SCD HeFT, COMPANION, MADIT, AVID and MUSTT.

Dr. Zelenkofske is the author or co-author of numerous articles published in professional journals, including the New England Journal of Medicine, Circulation, American Heart Journal and the European Heart Journal.  He is a practicing electrophysiologist at Lehigh Valley Hospital in Allentown, Pennsylvania, and serves as an associate professor of medicine at the College of Medicine of the Pennsylvania State University/Hershey Medical Center and for the Philadelphia College of Osteopathic Medicine.  Dr. Zelenkofske earned Bachelor of Science and Master’s degrees in biochemistry and immunopharmacology at Emory University.  He received a medical degree from the Philadelphia College of Osteopathic Medicine and holds certifications in clinical cardiac electrophysiology, cardiology and internal medicine.

About Regado Biosciences
Regado Biosciences is pioneering a new therapeutic field with the creation and development of two-component drug systems, comprising an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent.  Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect.  Enhanced control and flexibility allow physicians to meet the individual needs of patients independent of the setting.  Regado is focusing its discovery and development efforts on acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control.

Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin.

 

#      #      #